Summary
Becton Dickinson and Company (BDX) reported for the quarter ending June 30, 2001, showing a 4% increase in revenue to $954 million compared to the prior year's quarter. For the nine months ended June 30, 2001, revenue grew 2% to $2.76 billion. Revenue growth was somewhat dampened by foreign currency translation, which reduced reported revenues. Despite some regional economic headwinds and a decline in sales performance in Asia Pacific, the company saw broad-based growth across its key segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. The company maintained a strong financial position with total debt representing 36.4% of total capital as of June 30, 2001, a decrease from the previous year. Net income for the quarter rose to $124 million, or $0.46 per diluted share, compared to $114 million, or $0.43 per diluted share, in the prior year's quarter. Management highlighted disciplined expense management and a favorable tax rate contributing to the improved profitability.
Key Highlights
- 1Revenue increased 4% year-over-year to $954 million for the third quarter of fiscal year 2001.
- 2Net income for the third quarter rose to $124.3 million, or $0.46 per diluted share, up from $114.4 million, or $0.43 per diluted share, in the prior year.
- 3International revenues showed growth of 5% for the quarter, excluding the impact of unfavorable foreign currency translation.
- 4The Medical Systems segment saw revenue growth driven by advanced protection devices and consumer healthcare products.
- 5Clinical Laboratory Solutions revenue increased 6% for the quarter, bolstered by strong sales of advanced protection devices.
- 6Biosciences segment experienced robust 11% revenue growth, contributing to overall performance.
- 7Total debt as a percentage of total capital decreased to 36.4% as of June 30, 2001, indicating improved financial leverage.